

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumention Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1477)**

**VOLUNTARY ANNOUNCEMENT**  
**FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III**  
**CLINICAL TRIAL OF OT-802**

This announcement is made by Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that the phase III clinical trial of OT-802 (pilocarpine hydrochloride) in the People’s Republic of China (the “**PRC**”) has recently enrolled its first patient. The successful enrollment of the first patient marks an important milestone in the clinical development of OT-802 in the PRC, and demonstrates the Group’s commitment to advancing treatment of presbyopia.

OT-802, namely pilocarpine hydrochloride, is an innovative product independently developed by the Company for the treatment of presbyopia. According to preclinical studies, OT-802 demonstrates characteristics of rapid onset and a favorable safety profile. The Group applied the same dual-chamber liquid-liquid formulation technology used in OT-101 (0.01% atropine sulfate eye drop) to OT-802, effectively addressing product stability challenges. The Group possesses exclusive patent rights for this proprietary technology. The phase III clinical trial authorization of OT-802 was accepted by the Center for Drug Evaluation of the National Medical Products Administration of the PRC in June 2025.

**Cautionary Statement:** The Company cannot guarantee that it will be able to successfully develop or ultimately commercialize OT-802 (pilocarpine hydrochloride). Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Ocumention Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, May 28, 2026

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.*